Dorte K Holm1, Belinda K Moessner2, Ronald E Engle3, Hans L Zaaijer4, Jørgen Georgsen1, Robert H Purcell3, Peer B Christensen2. 1. Department of Clinical Immunology, Odense University Hospital, Odense, Denmark. 2. Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. 3. Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 4. Department of Blood-Borne Infections, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.
Abstract
BACKGROUND: The increasing incidence of reported hepatitis E cases in Europe has focused attention on hepatitis E virus (HEV) and the risk of transfusion-transmitted hepatitis E. The aim of this study was to investigate the prevalence of antibodies to HEV (anti-HEV) among Danish blood donors in 2013 and to compare it to previous studies in Denmark. In addition we wanted to compare the relative reactivity of two different assays. STUDY DESIGN AND METHODS: Samples from 504 blood donors were collected and analyzed for anti-HEV with an in-house assay developed at the National Institutes of Health (NIH). In addition the samples were analyzed with the Wantai anti-HEV assay. Demographic information and possible HEV exposure was collected by self-administered questionnaire. RESULTS: Using the NIH assay the prevalence of anti-HEV among Danish blood donors was 10.7% and with the Wantai assay the prevalence of anti-HEV was 19.8% (p < 0.001). In both cases the presence of anti-HEV was significantly correlated with increasing age. In addition, anti-HEV as measured by the Wantai test was significantly associated with contact with children (p = 0.01), but in multivariate analysis only age was associated with anti-HEV in both assays. By the NIH assay, the prevalence had declined from 20.6% in 2003 to 10.7% in 2013. CONCLUSIONS: Anti-HEV prevalence had decreased by half among Danish blood donors over 10 years, but was still highly prevalent. The difference in reactivity of the two assays demonstrates the importance of using the same assay when comparing the anti-HEV prevalence in populations over time.
BACKGROUND: The increasing incidence of reported hepatitis E cases in Europe has focused attention on hepatitis E virus (HEV) and the risk of transfusion-transmitted hepatitis E. The aim of this study was to investigate the prevalence of antibodies to HEV (anti-HEV) among Danish blood donors in 2013 and to compare it to previous studies in Denmark. In addition we wanted to compare the relative reactivity of two different assays. STUDY DESIGN AND METHODS: Samples from 504 blood donors were collected and analyzed for anti-HEV with an in-house assay developed at the National Institutes of Health (NIH). In addition the samples were analyzed with the Wantai anti-HEV assay. Demographic information and possible HEV exposure was collected by self-administered questionnaire. RESULTS: Using the NIH assay the prevalence of anti-HEV among Danish blood donors was 10.7% and with the Wantai assay the prevalence of anti-HEV was 19.8% (p < 0.001). In both cases the presence of anti-HEV was significantly correlated with increasing age. In addition, anti-HEV as measured by the Wantai test was significantly associated with contact with children (p = 0.01), but in multivariate analysis only age was associated with anti-HEV in both assays. By the NIH assay, the prevalence had declined from 20.6% in 2003 to 10.7% in 2013. CONCLUSIONS: Anti-HEV prevalence had decreased by half among Danish blood donors over 10 years, but was still highly prevalent. The difference in reactivity of the two assays demonstrates the importance of using the same assay when comparing the anti-HEV prevalence in populations over time.
Authors: Robert John Fontana; Ronald E Engle; Paul H Hayashi; Jiezhun Gu; David E Kleiner; Hahn Nguyen; Huiman Barnhart; Jay H Hoofnagle; Patrizia Farci Journal: Am J Gastroenterol Date: 2022-06-10 Impact factor: 12.045
Authors: Robert John Fontana; Ronald E Engle; Steven Scaglione; Victor Araya; Obaid Shaikh; Holly Tillman; Nahid Attar; Robert H Purcell; William M Lee Journal: Hepatology Date: 2016-06-23 Impact factor: 17.425
Authors: Pilar Clemente-Casares; Carlota Ramos-Romero; Eugenio Ramirez-Gonzalez; Antonio Mas Journal: Biomed Res Int Date: 2016-12-14 Impact factor: 3.411
Authors: Mark H Kuniholm; Edgar Ong; Boris M Hogema; Marco Koppelman; Kathryn Anastos; Marion G Peters; Eric C Seaberg; Yue Chen; Kenrad E Nelson; Jeffrey M Linnen Journal: Hepatology Date: 2016-01-16 Impact factor: 17.425
Authors: Johannes Hartl; Benjamin Otto; Richie Guy Madden; Glynn Webb; Kathy Louise Woolson; Levente Kriston; Eik Vettorazzi; Ansgar W Lohse; Harry Richard Dalton; Sven Pischke Journal: Viruses Date: 2016-08-06 Impact factor: 5.048